Bookmark

Media centre

Press releases

15/09/2005

Antisoma's preliminary results for the year ended 30 June 2005

15 September 2005, London, UK: Cancer drug developer Antisoma plc (LSE: ASM) today announces its preliminary results for the year ended 30 June 2005.

Highlights of 2004/2005

Advances across the pipeline

AS1404 enters phase II development in three cancers

Lung cancer study reaches patient recruitment target (in August 2005)
Prostate and ovarian cancer trials also on track

AS1411 phase I study reopened (in September 2005) after promising data reported at ASCO
AS1410 selected as lead telomere targeting agent and manufacturing agreement signed
AS1409 fully acquired from EMD-Lexigen collaboration and enters manufacturing

Acquisition strengthens portfolio

Aptamera acquired for £16.0 million in shares
Promising aptamer drug AS1411 added to pipeline

Financial highlights

Cash and liquid resources at 30 June 2005 of £25.0 million (2004: £38.8 million)
Full-year net loss of £7.1 million (2004: £0.6 million)
Revenues of £6.3 million (2004: £18.1 million)
Plan to list on NASDAQ announced; application made for US Level I ‘ADR’ programme

Commenting on the results, Glyn Edwards, Chief Executive Officer of Antisoma, said: “This has been a year of great progress. We have succeeded both in advancing our established pipeline products and in bringing in an exciting new drug, AS1411, through our acquisition of Aptamera. We look forward with confidence to a year including many important development milestones and results, starting with the first findings from our phase II study of AS1404 in lung cancer.”

Associated document (PDF, 207 KB, opens a new browser window)

Enquiries:

Antisoma plc
Glyn Edwards, Chief Executive Officer
Raymond Spencer, Chief Financial Officer
Daniel Elger, Director of Communications

+44 (0)20 8799 8200

Mark Court/Lisa Baderoon/Rebecca Skye Dietrich
Buchanan Communications (UK enquiries)

+44 (0)20 7466 5000

Richard Anderson
De Facto Communications (ex-UK enquiries)

+44 (0)20 7940 1000

Except for the historical information presented, certain matters discussed in this preliminary announcement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by this preliminary announcement. These risks and uncertainties may be associated with product discovery and development, including statements regarding the Company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.